Progress and challenges in RET-targeted cancer therapy

The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.

Automated summary

The rearranged during transfection (RET) is a receptor protein tyrosine kinase commonly found in non-small cell lung cancer and thyroid cancer. Two selective RET protein tyrosine kinase inhibitors, pralsetinib and selpercatinib, have been developed and approved for use. However, complete response rates to these inhibitors are low and resistance to them can occur through target mutations or alternative oncogene activation. Next-generation RET inhibitors are being tested, but the emergence of new resistance mutations remains a challenge. To address this, a better understanding of the mechanisms behind RET inhibitor tolerance is needed to develop effective co-treatment strategies.